MDS Nordion signs agreement to manufacture Molecular Insight's BMIPP

MDS Nordion, a part of MDS Inc., and Molecular Insight Pharmaceuticals Inc. of Cambridge, Mass., last week inked a development and contract manufacturing agreement to produce BMIPP. BMIPP is Molecular's lead molecular imaging pharmaceutical.

According to MDS, BMIPP is currently in a multi-center PhaseIIb clinical trial in the United States for the detection of cardiac ischemia in the emergency department setting. The compound has the ability to detect ischemia in chest pain patients at rest up to 30 hours after a cardiac event occurs.

BMIPP is labeled with MDS's high-purity iodine-123 to provide superior imaging quality. The new cardiac imaging pharmaceutical will be manufactured at MDS's cyclotron facility in Vancouver, Canada.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup